The current gold standard treatment is the surgical repair of the broken chords, which requires an open heart surgery at arrested heart with the help of a heart-lung machine.
This treatment leads to good results but still shows a number of unmet clinical needs like:
- Reduction of patient trauma
- Reduction of procedure time
- Reduction of the complexity of the procedure
- Reduction of operator dependency
- Reduction of recovery time for the patient
- Reduction of the “exclusion” of high risk as well as asymptomatic patients
CoreMedic is developing devices that are addressing all these unmet needs - the “ChordArt” family.
The basic concept consists of an implant that is used to replace the ruptured or elongated chordae of the valve and re-establishes the connection of the leaflet of the valve with the papillary muscle to restore the proper function.
CoreMedic is developing two systems that facilitate the safe and efficient delivery and deployment of the implant.
ChordArtTM S (S = surgical)
is aimed at reducing the invasiveness of the surgical procedure by repairing the valve in a fast, precise and safe way, allowing the surgeon to focus on the procedure and timing rather than manually placing the sutures to repair the valve.
ChordArtTM C (C = catheter)
is taking the treatment to a next level by reducing the invasiveness of the procedure even more. The goal here is to allow for the
valve repair to be carried out via the vascular route through a tiny incision in the groin, by trans-septal approach to the mitral valve, all the while performing the procedure on the beating heart without the need of a heart lung machine. This allows for a dramatically less traumatic treatment, leading to fewer risks for the patient, a faster recovery and results in heart failure (see FIGURE 1).
The ChordArtTM Advantages:
- reduces the complexity of the procedure by eliminating the manual suturing and knotting.
- is a minimally-invasive and much less traumatic procedure, which is faster and will obtain at least the same effectiveness as the current surgical standard
- represents a significant reduction in cost and improvement of economic value
- shows significant improvement in patient safety that will make mitral valve surgery accessible even for “high risk” and “asympto-matic” patients